Ocumension Therapeutics (HK:1477)
:1477
Want to see HK:1477 full AI Analyst Report?
1477 Stock Chart & Stats
HK$7.55
-HK$0.01(-0.25%)
At close: 4:00 PM EST
HK$7.55
-HK$0.01(-0.25%)
Day’s Range― - ―
52-Week RangeHK$5.60 - HK$12.23
Previous CloseN/A
Volume1.11M
Average Volume (3M)3.41M
Market Cap
HK$4.60B
Enterprise ValueHK$4.09B
Total Cash (Recent Filing)HK$402.63M
Total Debt (Recent Filing)HK$187.62M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Aug 20, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding836,331,900
10 Day Avg. Volume1,456,522
30 Day Avg. Volume3,406,832
Financial Highlights & Ratios
PEG Ratio0.68
Price to Book (P/B)1.43
Price to Sales (P/S)6.54
P/FCF Ratio-14.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$10.16Price Target Upside34.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.01
Revenue Forecast (FY)HK$1.10B
Bulls Say, Bears Say
Bulls Say
Revenue AccelerationSustained double‑digit top‑line growth signals improving commercial traction in ophthalmology indications. Over a 2–6 month horizon this supports scaled production, stronger pricing leverage and continuing R&D reinvestment, reducing execution risk as programs move toward commercialization.
Healthy Gross MarginsA mid‑40s gross margin indicates product and manufacturing economics that can absorb SG&A and R&D while preserving profitability upside. This margin profile is durable across quarters and provides a structural buffer as the company scales commercial activities and seeks positive operating leverage.
Low Financial LeverageExtremely low leverage gives the company financial flexibility to fund clinical, regulatory, and commercialization steps without heavy interest burdens. Over coming months this reduces refinancing risk, enables opportunistic investment, and limits solvency pressure during continued scale‑up.
Bears Say
Negative Cash FlowPersistent negative operating and free cash flow means the business cannot self‑fund growth and will rely on external capital. This creates ongoing financing risk and potential dilution, and constrains strategic optionality for M&A or accelerated commercialization over the next several quarters.
Ongoing Net LossesDespite narrowing losses, a structural negative net margin limits retained earnings and shareholder returns. Continued unprofitability pressures cash needs and may delay sustainable free cash flow generation, making long‑term operational self‑sufficiency dependent on sustained revenue momentum.
Negative Return On EquityA negative ROE signals the company is not yet converting equity investment into positive returns, which can hamper investor appetite and raise cost of capital. Structurally, this limits long‑term ability to attract favorable funding and may increase reliance on dilutive financing until profitability is achieved.
Ocumension Therapeutics News
1477 FAQ
What was Ocumension Therapeutics’s price range in the past 12 months?
Ocumension Therapeutics lowest stock price was HK$5.60 and its highest was HK$12.23 in the past 12 months.
What is Ocumension Therapeutics’s market cap?
Ocumension Therapeutics’s market cap is HK$4.60B.
When is Ocumension Therapeutics’s upcoming earnings report date?
Ocumension Therapeutics’s upcoming earnings report date is Aug 20, 2026 which is in 73 days.
How were Ocumension Therapeutics’s earnings last quarter?
Ocumension Therapeutics released its earnings results on Mar 26, 2026. The company reported -HK$0.046 earnings per share for the quarter, beating the consensus estimate of -HK$0.081 by HK$0.035.
Is Ocumension Therapeutics overvalued?
According to Wall Street analysts Ocumension Therapeutics’s price is currently Undervalued.
Does Ocumension Therapeutics pay dividends?
Ocumension Therapeutics does not currently pay dividends.
What is Ocumension Therapeutics’s EPS estimate?
Ocumension Therapeutics’s EPS estimate is -0.03.
How many shares outstanding does Ocumension Therapeutics have?
Ocumension Therapeutics has 836,331,900 shares outstanding.
What happened to Ocumension Therapeutics’s price movement after its last earnings report?
Ocumension Therapeutics reported an EPS of -HK$0.046 in its last earnings report, beating expectations of -HK$0.081. Following the earnings report the stock price went down -0.996%.
Which hedge fund is a major shareholder of Ocumension Therapeutics?
Currently, no hedge funds are holding shares in HK:1477
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ocumension Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
29.56%
12-Months-Change
Fundamentals
Return on Equity
-4.33%
Trailing 12-Months
Asset Growth
7.75%
Trailing 12-Months
Company Description
Ocumension Therapeutics
Based in the People's Republic of China, Ocumension Therapeutics functions as a dedicated ophthalmic pharmaceutical platform. This company, along with its subsidiaries, is committed to the research, progression, and market introduction of therapeutic solutions for individuals with various eye conditions. Its extensive product offerings target treatments for disorders such as blepharitis, infectious and allergic conjunctivitis, dry eye syndrome, cataracts, glaucoma, ocular hypertension, post-surgical inflammation, uveitis, retinitis pigmentosa, age-related macular degeneration, corneal graft rejection, myopia, and optic neuritis. By December 31, 2021, Ocumension Therapeutics boasted a pipeline of 20 drug assets. The company, founded in 2017, maintains its headquarters in Suzhou, China.
1477 Stock 12 Month Forecast
Average Price Target
HK$10.16
▲(34.57% Upside)
Technical Analysis
Jiangsu Recbio Technology Co., Ltd. Class H
―
Mabpharm Limited
―
Zhaoke Ophthalmology Ltd.
―
Transcenta Holding Limited
―
Shandong Boan Biotechnology Company., Limited. Class H
―
Options Prices
Currently, No data available
---